此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估 Bimekizumab 在活动性中轴性脊柱关节炎(包括强直性脊柱炎和非放射学中轴​​性脊柱关节炎)受试者中的长期安全性、耐受性和疗效的研究 (BE MOVING)

2026年11月2日 更新者:UCB Biopharma SRL

一项多中心、开放标签扩展研究,以评估 Bimekizumab 在治疗患有活动性中轴性脊柱关节炎、强直性脊柱炎和非放射学中轴​​性脊柱关节炎的研究参与者中的长期安全性、耐受性和疗效

The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).

研究概览

研究类型

介入性

注册 (实际的)

508

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国
        • As0014 20040
      • Chengdu、中国
        • As0014 20021
      • Guangzhou、中国
        • As0014 20019
      • Hefei、中国
        • As0014 20034
      • Nanjing、中国
        • As0014 20024
      • Shanghai、中国
        • As0014 20018
      • Shanghai、中国
        • As0014 20020
      • Shanghai、中国
        • As0014 20026
      • Wenzhou、中国
        • As0014 20025
      • Plovdiv、保加利亚
        • As0014 40006
      • Plovdiv、保加利亚
        • As0014 40007
      • Sofia、保加利亚
        • As0014 40005
      • Sofia、保加利亚
        • As0014 40008
      • Debrecen、匈牙利
        • As0014 40032
      • Szeged、匈牙利
        • As0014 40031
      • Székesfehérvár、匈牙利
        • As0014 40033
      • Ankara、土耳其(türkiye)
        • As0014 40052
      • Ankara、土耳其(türkiye)
        • As0014 40053
      • Istanbul、土耳其(türkiye)
        • As0014 40050
      • Berlin、德国
        • As0014 40025
      • Hamburg、德国
        • As0014 40029
      • Hanover、德国
        • As0014 40024
      • Herne、德国
        • As0014 40027
      • Leipzig、德国
        • As0014 40078
      • Ratingen、德国
        • As0014 40026
      • Brno、捷克语
        • As0014 40011
      • Pardubice、捷克语
        • As0014 40009
      • Prague、捷克语
        • As0014 40013
      • Prague、捷克语
        • As0014 40014
      • Prague、捷克语
        • As0014 40015
      • Prague、捷克语
        • As0014 40016
      • Uherské Hradiště、捷克语
        • As0014 40010
      • Zlín、捷克语
        • As0014 40012
      • Bunkyō City、日本
        • As0014 20035
      • Chūōku、日本
        • As0014 20030
      • Iruma-gun、日本
        • As0014 20039
      • Kawachi-Nagano、日本
        • As0014 20036
      • Kita-gun、日本
        • As0014 20045
      • Kitakyushu、日本
        • As0014 20065
      • Osaka、日本
        • As0014 20037
      • Saga、日本
        • As0014 20084
      • Saitama、日本
        • As0014 20048
      • Sapporo、日本
        • As0014 20031
      • Suita、日本
        • As0014 20032
      • Brussels、比利时
        • As0014 40004
      • Genk、比利时
        • As0014 40003
      • Ghent、比利时
        • As0014 40001
      • Boulogne-Billancourt、法国
        • As0014 40018
      • Limoges、法国
        • As0014 40022
      • Elblag、波兰
        • As0014 40038
      • Krakow、波兰
        • As0014 40042
      • Lublin、波兰
        • As0014 40037
      • Poznan、波兰
        • As0014 40044
      • Torun、波兰
        • As0014 40040
      • Warsaw、波兰
        • As0014 40041
      • Wroclaw、波兰
        • As0014 40039
      • Wroclaw、波兰
        • As0014 40043
    • Arizona
      • Glendale、Arizona、美国、85306
        • As0014 50062
      • Phoenix、Arizona、美国、85032
        • As0014 50052
    • California
      • Upland、California、美国、91786
        • As0014 50060
    • Florida
      • Ormond Beach、Florida、美国、32174
        • As0014 50059
      • Sarasota、Florida、美国、34239
        • As0014 50056
    • Maryland
      • Hagerstown、Maryland、美国、21740
        • As0014 50015
    • Missouri
      • St Louis、Missouri、美国、63141
        • As0014 50016
    • Oregon
      • Portland、Oregon、美国、97239
        • As0014 50055
    • Pennsylvania
      • Duncansville、Pennsylvania、美国、16635
        • As0014 50020
    • Texas
      • Dallas、Texas、美国、75231
        • As0014 50057
      • Edinburgh、英国
        • As0014 40057
      • Leeds、英国
        • As0014 40056
      • Norwich、英国
        • As0014 40055
      • Amsterdam、荷兰
        • As0014 40034
      • A Coruña、西班牙
        • As0014 40045
      • Córdoba、西班牙
        • As0014 40046
      • Santiago de Compostela、西班牙
        • As0014 40048
      • Seville、西班牙
        • As0014 40049

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
  • In the opinion of the Investigator, the study participant is expected to benefit from participation in this extension study
  • Study participant completed AS0010 (NCT03928704) or AS0011 (NCT03928743)

Exclusion Criteria:

  • Female study participants who plan to become pregnant during the study or within 20 weeks following final dose of Investigational Medicinal Product (IMP). Male study participants who are planning a partner pregnancy during the study or within 20 weeks following the final dose
  • Study participants who meet any withdrawal criteria in AS0010 or AS0011. For any study participant with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder study, the Medical Monitor must be consulted prior to the study participant's entry into AS0014
  • Study participant has a positive or indeterminate interferon gamma release assay (IGRA) in AS0010 or AS0011, unless appropriately evaluated and treated

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Bimekizumab

Subjects will receive bimekizumab throughout the Treatment Period.

Subjects will receive bimekizumab at prespecified time-points.

其他名称:
  • UCB4940
  • BKZ

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
大体时间:From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
Percentage of participants with serious adverse events (SAEs) during the study
大体时间:From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

  • Results in death
  • Is life-threatening
  • Requires in patient hospitalisation or prolongation of existing hospitalisation
  • Is a congenital anomaly or birth defect
  • Is an infection that requires treatment with parenteral antibiotics
  • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
Percentage of participants with with treatment-emergent adverse Events (TEAEs) leading to withdrawal from the study
大体时间:From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

次要结果测量

结果测量
措施说明
大体时间
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 28
大体时间:Week 28

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))-
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 concerning morning stiffness intensity and duration)
Week 28
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 52
大体时间:Week 52

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 52
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 112
大体时间:Week 112

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 112
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 28
大体时间:Week 28

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 28
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 52
大体时间:Week 52

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 52
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 112
大体时间:Week 112

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 112
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 28
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 52
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 112
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 28
大体时间:Week 28

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS40 domains.

Week 28
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 52
大体时间:Week 52

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

Week 52
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 112
大体时间:Week 112

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

Week 112
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 28
大体时间:Week 28

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

Week 28
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 52
大体时间:Week 52

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

Week 52
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 112
大体时间:Week 112

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.+ 1)

Week 112
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 28
大体时间:Week 28

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS40 domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 28
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 52
大体时间:Week 52

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 52
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 112
大体时间:Week 112

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 112
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 28
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 52
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 112
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 28
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 52
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 112
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 28
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 52
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 112
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 28
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 52
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 28
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 52
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 112
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 28
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 52
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 112
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 112
大体时间:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:UCB Cares、001 844 599 2273 (UCB)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年6月16日

初级完成 (实际的)

2026年8月9日

研究完成 (实际的)

2026年8月9日

研究注册日期

首次提交

2020年6月15日

首先提交符合 QC 标准的

2020年6月15日

首次发布 (实际的)

2020年6月18日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • AS0014
  • 2019-004163-47 (EudraCT编号)
  • 2023-506527-28 (注册表标识符:EU Clinical Trials)
  • U1111-1304-6865 (其他标识符:World Health Organization (WHO))
  • 2023 (美国 NIH 拨款/合同)
  • 2019 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

IPD 共享时间框架

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD 共享访问标准

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅